Extracorporeal photopheresis (ECP) is a leukapheresis-based therapeutic procedure that has been approved by the US Food and Drug Administration (FDA) for the treatment of advanced cutaneous T-cell lymphoma (CTCL) since 1988. ECP, also known as extracorporeal photochemotherapy and extracorporeal photoimmunotherapy, is performed at over 200 cen...
This is an open-label study (patients and study staff will know the identity of treatments assigned during the study) in patients with chronic graft-versus-host disease (cGvHD). Chronic graft-versus-host disease (a donator-versus-recipient-disease) is a complication that can occur after a blood stem cell or bone marrow transplant with cells from a related or unrelated donator. During cGvHD, the transplanted cells attack the recipients body. Patients with cGVHD who meet entry criteria for the study will be randomly assigned to receive standard of care treatment for 26 weeks or standard or care treatment with extracorporeal photopheresis (ECP) for 26 weeks. Standard of care treatment consists of orally (taken by mouth) administered corticosteroids (drugs that reduce inflammation) and cyclosporine (CsA)or Tacrolimus ( drugs that suppress the patients immune response). ECP therapy is a process that takes place in a device where the investigational drug UVADEX (methoxsalen) is injected into a ...
Reinisch, W., Knobler, R., Rutgeerts, P. J., Ochsenkühn, T., Anderson, F., von Tirpitz, C., Kaatz, M., van der Woude, C. J., Parenti, D. and Mannon, P. J. (2012), Extracorporeal photopheresis (ECP) in patients with steroid-dependent Crohns disease: An open-label, multicenter, prospective trial. Inflamm Bowel Dis. doi: 10.1002/ibd.23012 ...
This trial evaluated the efficacy of extracorporeal photopheresis [methoxsalen], pentostatin, and total body irradiation versus pentostatin and total body
We have developed an improved porphyrin precursor based method for extracorporeal photopheresis (ECP), for treatment of cutaneous T-cell lymphoma (CTCL), graft versus host disease (GvHD), transplant rejection and other selected autoimmune diseases.
In this article, we report the novel finding that ECP promotes release of mature IL-1β. IL-1β is a key immunostimulatory molecule belonging, along with IL-1α, IL-18, IL-36, and IL-37, to the IL-1 family (36). IL-1β is primarily produced by myeloid cells and represents a central mediator of antimicrobial resistance, inflammation, and Th 17 differentiation (36). Several reports have revealed the immunoregulatory capacity of ECP via Treg induction, but little is known regarding the induction of immunostimulatory mediators by ECP (10-12).. Different groups have reported that ECP promoted the differentiation and partial maturation of DC based on surface costimulatory molecule expression, migratory activity, and Ag presentation assays (13, 37, 38). Of interest, Holtick et al. (37) reported an increased immunostimulatory and migratory capacity of ECP-treated monocyte-derived DC. Furthermore, with respect to survival and apoptosis, our results indicated selective survival of CD14+ monocytes after ...
CTCL is a group of lymphoproliferative disorders caused by clonally derived, skin-homing, malignant T cells. The most common of these disorders is mycosis fungoides (60%) and its leukemic variant, S&e... more
The report offers a comprehensive evaluation of the market. Increasing applications of photopheresis products market in the medical world are bolstering the market in developed regions. photopheresis products market represents the fastest growing market since the past few years.
... Russia Photopheresis Products Market: Prospects, Trends Analysis, Market Size and Forecasts - Market research report and industry analysis - 12887367
BACKGROUND: Extracorporeal photochemotherapy (EPC) has recently been proposed for the treatment of adults with either acute or chronic GVHD. However, data on children given this therapy are scarce. A Phase I-II study was carried out on EPC in children experiencing GVHD after allogeneic transplantation of HPCs.. STUDY DESIGN AND METHODS: Nine patients with steroid-resistant, grade II-IV acute GVHD and 14 with chronic GVHD, all of whom had been refractory to at least one line of treatment, were enrolled in this study and analyzed. The median age was 10.3 years (range, 5.4-18.1), and the median body weight was 35 kg (range, 17-89).. RESULTS: Seven of the nine patients with acute GVHD showed a response to EPC, whereas the disease progressed in the remaining two children (both with skin, gastrointestinal, and liver GVHD), and they died of grade IV acute GVHD. Among the seven children who responded to EPC, it was possible to completely discontinue immunosuppressive treatment in three. In the 14 ...
Background: Chronic graft-versus-host disease (cGvHD) is the leading cause of late nonrelapse mortality (transplant-related mortality) after hematopoietic stem cell transplant. Given that there are a wide range of treatment options for cGvHD, assessment of the associated costs and efficacy can help clinicians and health care providers allocate health care resources more efficiently. Objective: The purpose of this study was to assess the cost-effectiveness of extracorporeal photopheresis (ECP) compared with rituximab (Rmb) and with imatinib (Imt) in patients with cGvHD at 5 years from the perspective of the Spanish National Health System. Methods: The model assessed the incremental cost-effectiveness/utility ratio of ECP versus Rmb or Imt for 1000 hypothetical patients by using microsimulation cost-effectiveness techniques. Model probabilities were obtained from the literature. Treatment pathways and adverse events were evaluated taking clinical opinion and published reports into consideration. ...
Extracorporeal photopheresis (ECP) has demonstrated efficacy as second-line treatment for steroid-refractory (SR) acute graft-versus-host disease (aGVHD). The aim of our study was to analyze whether the amount of ECP-treated cells in patients with SR, aGVHD has an impact on response at 1 month. Data on white blood cells, lymphocytes, monocytes, mononuclear cells, and neutrophils, including absolute counts and counts per kilogram of body weight in ECP products from patients with aGVHD, were collected. For each cell population, the median dose per single ECP and the cumulative doses collected during the first week and the first month of treatment were compared with the response to ECP. In total, 99 patients underwent 1215 ECP procedures. Overall response was defined as a complete response if all signs of aGVHD resolved or a partial response if greater than 50% resolution was reached without other, additional immunosuppression. An overall response was obtained by 75% of patients, including 53% ...
The study objective is to demonstrate that the UVADEX® Sterile Solution formulation of methoxsalen used in conjunction with the UVAR XTS Photopheresis
See Important Safety Information and Prescribing Information, including the BOXED WARNING, for UVADEX®. Hear how Anita is poised and ready to treat her CTCL skin symptoms with THERAKOS® Photopheresis.
Extracorporeal photopheresis (ECP) is established therapy for palliation of cutaneous T-cell lymphoma, and also effective in other T-cell mediated diseases such as acute and chronic graft-versus-host disease. Indications for use of ECP in acute and chronic rejection in lung transplantation have not been established. This prospective observational study compared rate of change in lung function […]. ...
Graft-versus-host disease (GvHD) is a major barrier to the successful outcome of allogeneic haematopoietic stem cell transplantation. This thesis investigates four novel strategies for managing GvHD: the role of extracorporeal photopheresis (ECP), the use of economic data to allow for funding of new treatments, the impact of a new dedicated GvHD clinic and the writing of national guidelines. The main hypothesis is that fortnightly ECP would improve signs and symptoms of chronic GvHD. A single centre retrospective analysis of 82 patients showed that this ECP schedule was effective with 94% of patients who completed 6 months of treatment achieving a complete or partial response. The information derived from this study was subsequently used to design a study to test this hypothesis in a prospective cohort of patients. 70% of patients who completed 6 months of ECP had a complete or partial response. Analysis of quality of life in a subset of patients showed a significant improvement in chronic GvHD ...
Background: HemoCue point of care devices has been extensively used in screening for anemia in blood banking. HemoCue can estimate hemoglobin (Hb) both from venous as well as capillary blood. However, the suitability of HemoCue Hb estimation in donor selection is unclear. Aims: The aims of this study were to evaluate variance of difference in Hb measurement in capillary HemoCue estimation as compared to venous HemoCue estimation from automated cell counter and to assess accuracy of two different HemoCue models (201 and 301) against automated cell counter Hb measurements in both capillary as well as venous blood. Materials and Methods: HemoCue 201 and 301 were evaluated by a comparison of methods study against Sysmex XP-100 three-part analyzer at a blood bank of a tertiary care hospital in Uttarakhand, India, in 2017. Assessment for anemia of 115 donors was done initially by capillary Hb by a convenience sampling to 2 instruments from 2 different models of HemoCue (total of 4 instruments). Venous ...
MANCILLA, Paulina; ACOSTA, Agustina and ALVAREZ, Mariela. Narrowband UVB phototherapy for the treatment of cutaneous chronic graft versus host disease: case report. Arch. Pediatr. Urug. [online]. 2017, vol.88, n.6, pp.329-334. ISSN 0004-0584. http://dx.doi.org/10.31134/ap.88.6.5.. Chronic graft-vs-host disease (GVHD) is a frequent complication in patients who receive allogeneic hematopoietic cell transplants (HCTs), and the skin is the most common site of involvement. Chronic cutaneous GVHD can present with sclerotic or nonsclerotic changes and often requires treatment with systemic immunosuppressants, extracorporeal photopheresis, or phototherapy. Immunosuppressants carry the potential of causing important side effects, so additional modes of therapy with better security profiles are clearly needed. We report a case of an eleven year old girl, who received allogeneic HCTs to treat acute lymphocytic leukemia. She developed sclerotic chronic GVHD. The patient underwent treatment with narrowband ...
Andrew Gennery spent a year of post-doctoral studies working with Anne Durandy and Alain Fischer in the Necker Hospital in Paris and was involved in the discovery of Cytidine Deaminase one of the first genes to be discovered involved in class switch recombination and somatic hypermutation. His research interests include immunoreconstitution following haematopoietic stem cell transplant for primary immunodeficiency, long-term outcomes of transplantation for primary immunodeficiency DNA repair disorders and their appropriate treatment. He has adapted new methods of T-cell depletion for patients with primary immunodeficiency, and established extracorporeal photopheresis for the treatment of children with graft versus host disease. He is a member of ESID and EBMT and currently chairs the ESID/EBMT Inborn Errors Working Party group. He has written international guidelines for the treatment of patients with DNA repair disorders and CD40 ligand deficiency. He is currently part of the working group ...
(2016) Flinn, Gennery. F1000Research. Acute graft-versus-host disease (aGvHD) continues to be a major obstacle to allogeneic haematopoietic stem cell transplantation. Thymic damage secondary to aGvHD along with corticosteroids and other non-selective T lymphocyte-suppressive agents used in the tr...
We hypothesized that activated platelets induce monocyte-to-dendritic cell (DC) differentiation. The aims of this study were to: (1) determine the role that platelets play, if any, in the signaling of monocyte to DC differentiation; (2) determine the mechanism of action by which platelets induce monocyte-to-DC differentiation. (3) Use this knowledge to advance cancer immunotherapy. To achieve these ends: (1) parallel-plate flow chambers were designed to deliver monocytes a controlled level of platelet exposure, with phenotype and genotype assessed following overnight incubation; (2) blocking antibodies and proteins were used to assess for the significance of particular monocyte-platelet interactions in the mechanism; (3) additional experiments and mathematical modeling was performed to extrapolate our new mechanistic knowledge to enhance extracorporeal photochemotherapy (ECP), an immunotherapy in clinical use. Results showed direct correlation between platelet exposure and level of DC differentiation
Jan 5, 2010: Edward Chu, M.D. - Chinese Herbal Medicine in the Treatment of G.I. Cancer: From Bench to Bedside. Jan 5, 2010: Joanne B. Weidhaas, M.D., Ph.D. - The KRAS-variant and Cancer Risk. Feb 2, 2010: Nina S. Kadan-Lottick, M.D., M.S.P.H. - The Yale HEROS Clinic: A Clinical and Research Program for Childhood Cancer Survivors. Feb 2, 2010: Richard L. Edelson, M.D. - Personalized Dendritic Cell Immunotherapy: Deciphering the Scientific Mechanism of Extracorporeal Photochemotherapy. Feb 9, 2010: Gil G. Mor, M.D., Ph.D. - Role of Ovarian Cancer Stem Cells in Recurrence and Metastasis. Feb 9, 2010: Lyndsay N. Harris, M.D. - Breast Cancer Genomics: Therapeutic Applications. Feb 16, 2010: Peter M. Glazer, M.D., Ph.D. - Hypoxia, DNA Repair and Cancer Therapy. Feb 16, 2010: Bryan W. Chang, M.D. - Stereotactic Body Radiation Therapy (SBRT) for Liver Tumors. Feb 23, 2010: Madhav Dhodapkar - Stemness, Inflammation and Tumor Immunity: From Bedside to the Bench and Back. Feb 23, 2010: David G. Schatz, ...
As I sat at the doctors office that Monday, getting the 5 hour CMV infusion and the brush fire suppressant, I was pretty discouraged. Then a big, burly, healthy looking man with tattoos on his neck and a larger than life personality, took a chair for a treatment. Listening to him talk with another man who was donating stem cells, I learned that hes had a really rough GVHD journey. His GVHD attacked his gut and ate into his intestines, requiring surgeries and other awful procedures. He also went blind and had to have the inner lenses of his eyes surgically repaired so that he could see again. Now hes getting treated with a process called photopheresis. This is very effective for bad cases of GVHD, in that it siphons off the patients blood from one arm, treats the T cells in that blood (where GVHD is found) with a special drug, after which ultraviolet light is then used to clean everything up and the blood is then returned to the patient in the other arm. The problem is that these treatments ...
I finally got to see a dermatologists and got my skin checked. Well, once the derm seen all of my path reports she suggested that I might have to have MOHS Surgery because she felt my margins werent big enough. My melanoma was quite thin and the intial biopsy itself had clear margins. Then I had my WLE done and it came back completely clear as well. Why in the world would I have to have MOHS done? Then while she was checking me she marked two more places on my back and done shave biopsies on them. Why would she do that knowing my history with melanoma?
Learn about the different Apheresis procedures available at Inova including Extracorporeal Photopheresis (ECP), Leukapheresis (White Blood Cell Depletion), Plasmapheresis (Therapeutic Plasma Exchange), Plateletpheresis (Platelet Depletion), Red Blood Cell (RBC) Exchange and Therapeutic Phlebotomy.
fō-tō-fŏr-ē′sĭs) A technique used in treating cutaneous T-cell lymphoma. It incorporates exposure of a lymphocyte-enriched blood fraction, obtained by use of apheresis to ultraviolet A light after the patient has ingested the cytotoxic agent 8-methoxypsoralen. SYN: extracorporeal photochemotherapy. ...
Lung anniversary (126) travelling (123) Lungfunctions/ FEV1% (93) BOS/Chronic Rejection (91) Jozi (75) Visits to Port Elizabeth (53) Media stuff (42) Cystic Fibrosis (41) photopheresis (37) sadness (36) World Transplant Games 2009 (33) transplant hospitalisation (32) 30 day pic challenge (31) post transplant hospitalisation (31) #StayStrong (28) USA trip 2015 (26) pre-transplant pics of me (25) Inspiration (24) pre-transplant (24) World Transplant Games 2011 (23) Chistmas (22) World Transplant Games 2013 (21) Birthdays (18) Love Life; Gift Life (18) Being an Aunt (16) Pseudomonas Aeruginosa (16) colouring in (16) Our Wedding (14) I hate my cervix (13) resolutions (13) YouTube (12) crochet (12) reflux (12) Second Transplant (10) UK Trip 2012 (10) Anxiety (9) UK Trip 2011 (9) wedding anniversary (9) Acute Rejection (7) World Transplant Games 2015 (7) SA Blog Awards 2008 (5) bucket-list (4) Breathe Composition by Brian Mark (3) World Transplant Games 2019 (3) ...
Lung anniversary (126) travelling (123) Lungfunctions/ FEV1% (93) BOS/Chronic Rejection (91) Jozi (75) Visits to Port Elizabeth (53) Media stuff (42) Cystic Fibrosis (41) photopheresis (37) sadness (36) World Transplant Games 2009 (33) transplant hospitalisation (32) 30 day pic challenge (31) post transplant hospitalisation (31) #StayStrong (28) USA trip 2015 (26) pre-transplant pics of me (25) Inspiration (24) pre-transplant (24) World Transplant Games 2011 (23) Chistmas (22) World Transplant Games 2013 (21) Birthdays (18) Love Life; Gift Life (18) Being an Aunt (16) Pseudomonas Aeruginosa (16) colouring in (16) Our Wedding (14) I hate my cervix (13) resolutions (13) YouTube (12) crochet (12) reflux (12) Second Transplant (10) UK Trip 2012 (10) Anxiety (9) UK Trip 2011 (9) wedding anniversary (9) Acute Rejection (7) World Transplant Games 2015 (7) SA Blog Awards 2008 (5) bucket-list (4) Breathe Composition by Brian Mark (3) World Transplant Games 2019 (3) ...
Dr. Girardi received his combined (B.S. in Biology, B.A. in Computer Science) undergraduate degree from Brown University in 1988, graduating magna cum laude (highest honors). He received his M.D. from Yale University School of Medicine in 1992, graduating with Honors / Top Thesis Award. After completing a research fellowship at Yale, and residency training in Dermatology at Yale-New Haven Hospital in 1997, Dr. Girardi joined the faculty of the Yale School of Medicine, Department of Dermatology, where he is now a full Professor, Clinical-Scholar Track, and Director of Residency Training. Dr. Girardi is also the Director of the Yale Photopheresis Unit, a specialized blood treatment center for leukemia/lymphoma of the skin and other immune mediated disorders, and an active member of the Yale Cancer Center. He directs a research laboratory funded by the National Cancer Institute, studying immune mechanisms of cancer development and progression.. ...
Extracorporeal photochemotherapy (ECP) is a therapeutic procedure which combines leukapheresis and PUVAtherapy (psoralen plus UVA radiation). This novel form of cell therapy consists of collection of mononuclear cells and their irradiation with UVA in the presence of a photoactivable molecule (8-methoxypsoralen), before being reinfused. ECP was developed to induce a modulation of immune response similar to that observed after in vivo phototherapy. The photophoresis procedure requires three steps including white blood cells collection, and the precise control of psoralen concentration and UVA dose. Advantages and inconvenients of the two ECP procedures available for human use are respectively discussed. Mechanisms of action of ECP are currently incompletely defined and different hypotheses are suggested. On the molecular level, DNA, cell membrane, and cytoplasm are involved in the biologic effects of EPC. The therapeutic effect of ECP is likely induced by the combination of different bi ological ...
The Division also provides 24-hour consultation, execution, and monitoring of therapeutic apheresis procedures to all UCD clinical services, as well as other health systems in the greater Sacramento area. Therapies include plasma exchange, red cell exchange, leukoreduction and platelet reduction in addition to photopheresis. Members of the division are also involved in clinical apheresis research.. In addition to contributing to the professional development of the transfusion medicine fellow, members of the apheresis faculty are involved in teaching pathology residents and other medical trainees in the clinical applications and appropriate use of this specialized therapeutic modality.. Contact Apheresis Services at 916-734-3732.. ...
The safety of psoralen photochemotherapy (PUVA) in relation to the eye has been an area of research at the Washington Hospital Center for the last 6 years. Our studies indicate that, with proper shielding of the eye, safety for acute lenticular damag
There is a clear need for effective, steroid-sparing agents for the management of chronic graft-versus-host disease (GVHD). Thus, agents like Histone d
Лечение интерлейкином-2 рефрактерной хронической реакции трансплантат-против-хозяинаTreatment of refractory chronic graft-versus-host disease with interleukin-2
FDA Grants Breakthrough Therapy Designations to Two Therapies for Acute and Chronic Graft-Versus-Host Disease - Latest & Greatest, News - ASH Clinical News
Company Remains on Track to Report Interim Analysis by End of 2019 NEW YORK, NY / ACCESSWIRE / August 13, 2019 / Kadmon Holdings, Inc. (NYSE:KDMN) today
We offer clinical cancer updates, treatment guidance, and research news to the oncology nursing community. Visit us often for drug therapy testing results, patient care information and more. Download our FREE app today.
Whangbo JS, Kim HT, Mirkovic N, Leonard L, Poryanda S, Silverstein S, Kim S, Reynolds CG, Rai SC, Verrill K, Lee MA, Margossian S, Duncan C, Lehmann L, Huang J, Nikiforow S, Alyea EP, Armand P, Cutler CS, Ho VT, Blazar BR, Antin JH, Soiffer RJ, Ritz J, Koreth J. Dose-escalated interleukin-2 therapy for refractory chronic graft-versus-host disease in adults and children. Blood Adv. 2019 09 10; 3(17):2550-2561 ...
Average onset of chronic graft-versus-host disease (cGVHD)was 8.2±4 months in Scl-GVHD and 6.7±4 in non-Scl-cGVHD. Average Modified Rodnan Skin Score was 8.2 in Scl-GVHD, 12 in SSc and 0 in non-Scl-GVHD. Histopathological analysis of Scl-GVHD confirmed full thickness skin fibrosis in the presence of a more dense tissue infiltrate and the absence of the fibroproliferative vasculopathy and vessel rarefication peculiar of SSc. On the contrary non-Scl-GVHD showed intense tissue infiltrate and neither tissue fibrosis nor fibroproliferative vasculopathy. AIF-1 expression was significantly increased in both Scl- and non-Scl-cGVHD. The pattern of expression was mostly in perivascular and tissue infiltrating mononuclear cells, whereas microvascular endothelial cells (MVECs) did not show any AIF-1 expression despite what has been previously shown in SSc. Cav-1 expression was profoundly decreased in both SSc and Scl-GVHD whereas it was conserved in non-Scl-GVHD.. ...
Our providers at the Dermatology Clinic assess and treat a full range of skin conditions, including consultation for skin diseases and cosmetic problems, diagnostic studies, photochemotherapy, surgery for benign or malignant skins conditions.
Cancer Therapy Advisor provides oncologists and oncology specialists with the latest information to correctly diagnose the latest cancer conditions, recommend procedures and guides. Visit often for updates and new information.
Clinical trial for Hematopoietic Stem Cell Transplantation | Multiple Myeloma , Ixazomib in the Prophylaxis of Chronic Graft-versus-host Disease.
Logical Images, Inc. d/b/a VisualDx (hereinafter "VisualDx", "we", "us", or "our") has created this Acceptable Use Policy, Medical Disclaimer, & Copyright Notice (this "Notice") to inform you (hereinafter "you", "your", or "yourself") as a purchaser of a license for and/or user of the software hosted by VisualDx known as VisualDx (the "Software") of certain important terms and conditions set forth in the VisualDx End User License Agreement that governs your license for and/or use of the Software (the "EULA"). This Notice is subject to all of the terms and conditions set forth in the EULA and does not replace or limit it in anyway. You should read the EULA in detail prior to purchasing a license for or using the Software to make sure you understand and agree to its terms and conditions. Nothing in this Notice will (a) expand your rights or VisualDx′s obligations under the EULA or (b) modify or otherwise affect any terms and conditions of the EULA or the rights of the parties under the EULA. In ...
TY - JOUR. T1 - Stimulatory autoantibodies to PDGF receptor in patients with extensive chronic graft-versus-host disease. AU - Svegliati, Silvia. AU - Olivieri, Attilio. AU - Campelli, Nadia. AU - Luchetti, Michele. AU - Poloni, Antonella. AU - Trappolini, Silvia. AU - Moroncini, Gianluca. AU - Bacigalupo, Andrea. AU - Leoni, Pietro. AU - Avvedimento, Enrico V.. AU - Gabrielli, Armando. PY - 2007/7/1. Y1 - 2007/7/1. N2 - Extensive chronic graft-versus-host disease (ecGVHD) is characterized by fibrosis similar to that of patients with systemic sclerosis (scleroderma). Since stimulatory autoantibodies against the platelet-derived growth factor (PDGF) receptor (PDGFR) have been found in patients with scleroderma and are responsible for the activation of skin fibroblasts, we tested the hypothesis that these autoantibodies are also present in patients affected by ecGVHD. Serum from 39 patients subjected to allogeneic stem cell transplantation for hematologic malignancies (22 with ecGVHD and 17 ...
Microsatellite polymorphism (CA)n within the first intron of the interferon- gamma gene was assessed in 160 recipients of an allogeneic hematopoietic stem cell transplant (HSCT). IFN- gamma 3/3 was found to be associated with an increased risk of chronic graft-versus-host disease (GvHD) (11/27 vs 26/133, p=0.02). Forward logistic regression analysis confirmed the role of IFN-gamma 3/3 genotype as one of the risk factors for manifestation of chronic GvHD (OR=3.180, p=0.018) together with previous acute GvHD (OR=2.752, p=0.024), cyclosporine A monotherapy (OR=2.607, p=0.029) and malignant disorders (OR=4.371, p=0.032).. ...
BACKGROUND: New criteria for the diagnosis and classification of chronic graft-versus-host disease were developed in 2005 for the purpose of clinical trials with a consensus sponsored by the National Institute of Health. OBJECTIVES: The aim of this study is to present the results of a multicenter pilot study performed by the Brazil-Seattle chronic graft-versus-host disease consortium to determine the feasibility of using these criteria in five Brazilian centers. METHODS: The study was performed after translation of the consensus criteria into Portuguese and training. A total of 34 patients with National Institute of Health chronic graft-versus-host disease were enrolled in the pilot study between June 2006 and May 2009. RESULTS: Of the 34 patients, 26 (76 percent) met the criteria of overlap syndrome and eight (24 percent) the classic subcategory. The overall severity of disease was moderate in 21 (62 percent) and severe in 13 (38 percent) patients. The median time from transplant to onset of ...
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details ...
A Phase 3 study evaluating dupilumab (Dupixent; Sanofi Regeneron) in adults and adolescents with severe, steroid-dependent asthma
Chronic graft-versus-host disease (cGVHD) is a debilitating complication arising in around half of all patients treated with an allogeneic hematopoietic stem cell transplantation. Even though treatment of severe cGVHD has improved during recent years, it remains one of the main causes of morbidity and mortality in affected patients. Biomarkers in blood that could aid in the diagnosis and classification of cGVHD severity are needed for the development of novel treatment strategies that can alleviate symptoms and reduce the need for painful and sometimes complicated tissue biopsies. Methods that comprehensively profile complex biological systems such as the immune system, can reveal unanticipated markers when used with the appropriate methods of data analysis. Here, we used mass cytometry, flow cytometry, ELISA and multiplex assays to systematically profile immune cell populations in 68 patients with varying grades of cGVHD. We identified multiple subpopulations across T, B and NK-cell lineages that
One of the most basic treatments is topical steroid therapy, which involves the use of steroid cream on the white patches of the skin. This may help to re-pigment the skin; however, results come very slowly (after several months). In addition, steroids are associated with a number of side effects, including a weakened immune system and skin irritation. A more advanced treatment involves photochemotherapy in combination with oral or topical psoralen. Although this approach is generally more effective than steroid therapy, it is also much more time-consuming, expensive and is associated with severe side effects including skin burns, eye damage and skin cancer. There are also a number of surgical therapies for vitiligo, such as skin grafting. Again, this is not always effective as the graft may be rejected. Surgical procedures can also have complications such as infections, scarring, and cobblestoned skin appearance. ...